Skip to main content
Aprogen, Inc logo

Aprogen, Inc — Investor Relations & Filings

Ticker · 007460 ISIN · KR7007460009 KO Manufacturing
Open in API
Filings indexed 737 across all filing types
Latest filing 2022-07-18 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 007460

About Aprogen, Inc

https://www.aprogen.com/en/v.do?a=Main

Aprogen, Inc. is a biopharmaceutical company focused on the research, development, and manufacturing of biologic medicines. The company's core activities are centered on developing both biosimilars and novel drugs, including new protein therapeutics and bispecific antibodies. Its product development is based on proprietary technologies in antibody engineering and recombinant protein engineering.

Recent filings

Filing Released Lang Actions
증권발행실적보고서(합병등)
Share Issue/Capital Change Classification · 100% confidence The document is a '증권발행실적보고서' (Report on the Results of Securities Issuance) related to a merger (합병). It details the merger schedule, changes in major shareholding, stock purchase rights (주식매수청구권), and the issuance of new shares. This is a formal regulatory filing submitted to the Financial Supervisory Service (금융감독원) in South Korea, documenting the completion of a corporate action (merger). Since it is a specific regulatory report regarding the issuance of securities following a merger, it falls under the 'Regulatory Filings' category.
2022-07-18 Korean
합병등종료보고서(합병)
M&A Activity Classification · 100% confidence The document is a 'Report on the Completion of Merger' (합병등종료보고서) filed with the Financial Supervisory Service (FSS) in South Korea. It details the finalization of a merger between Aprogen and Aprogen Medicines, including the merger schedule, changes in shareholding, stock purchase rights, and creditor protection measures. This type of filing is a standard regulatory disclosure required upon the completion of a corporate merger, which falls under the 'Regulatory Filings' category as it is a specific legal reporting requirement for corporate actions.
2022-07-18 Korean
대표이사(대표집행임원)변경(안내공시)
Board/Management Information Classification · 100% confidence The document is a formal announcement regarding the change of the company's CEO (Representative Director). It explicitly lists the former CEO, the new CEO, the reason for the change, and the effective date. This falls directly under the definition of Board/Management Information (MANG).
2022-07-18 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the appointment and resignation of outside directors (사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고). This falls under the category of Board/Management Information, which covers changes in the company's board of directors.
2022-07-18 Korean
최대주주등소유주식변동신고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Change in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) filed by Aprogen MED. It details specific changes in share ownership for major shareholders and related parties due to a merger. This type of filing is a regulatory requirement for disclosing significant changes in ownership structure, which falls under the 'Major Shareholding Notification' category.
2022-07-18 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a mandatory regulatory filing in South Korea under Article 147 of the Capital Markets Act. It details changes in share ownership, including major shareholders and special related parties, and specifies the purpose of holding (management influence). This fits the definition of a Major Shareholding Notification.
2022-07-15 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.